Federal drug enforcement authorities will continue defining marijuana as a drug with a high potential for abuse and no accepted medical value, a decision that keeps in place significant restrictions on biomedical research.

The decision by the Drug Enforcement Administration, reported by news outlets late Wednesday, means marijuana will remain classified as a Schedule 1 drug. A formal announcement is expected Thursday.

Many scientists have been calling for the federal government to reschedule the drug, which they said would open the door to more medical research into marijuana and its potential effects, both beneficial and harmful.

To conduct research with Schedule 1 drugs, scientists have to gain DEA approval and often upgrade the security protocols in their labs, expensive and time-consuming hurdles.

Scientists have argued that thorough research is all the more important with medical marijuana available in 25 states and Washington, and a small number of states starting to legalize recreational marijuana as well.

Researchers also need the highest level of permission to run clinical trials of marijuana and drugs derived from it, and to study constituents of marijuana, even if they are free of the components that make people high.

A component of marijuana called cannabidiol has shown promise […]

Read the Full Article